5-HT4 receptor agonist for gastroparesis

The present invention, for use in the treatment of the human body 4 - {[4 - ({[4- (2,2,2-trifluoroethoxy) -1,2-benzisoxazole-3-yl] oxy} methyl) about piperidin-1-yl] methyl} tetrahydro -2H- pyran-4-carboxylic acid. In particular, for the treatment of gastroparesis, or relating to the compound having useful selective 5-HT4 receptor agonism in order to prevent or delay the onset or progression of gastroparesis.